---
title: Efficiency of Art-therapy in Psychotic Disorders
nct_id: NCT02383095
overall_status: TERMINATED
phase: NA
sponsor: University Hospital, Strasbourg, France
study_type: INTERVENTIONAL
primary_condition: Schizophrenia
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02383095.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02383095"
ct_last_update_post_date: 2019-10-21
last_seen_at: "2026-05-12T07:13:38.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Efficiency of Art-therapy in Psychotic Disorders

**NCT ID:** [NCT02383095](https://clinicaltrials.gov/study/NCT02383095)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** Difficulties of recruitment
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 9
- **Lead Sponsor:** University Hospital, Strasbourg, France
- **Conditions:** Schizophrenia
- **Start Date:** 2015-05-27
- **Completion Date:** 2019-10
- **CT.gov Last Update:** 2019-10-21

## Brief Summary

The main purpose of the protocol is to test the efficiency of art-therapy versus metacognitive rehabilitation on the visual perception disorders observed in patients with schizophrenia.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 55 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* schizophrenia according to DSM IV

Exclusion Criteria:

* addiction problem
* invalidating visual sensory problems
* neurological history
```

## Arms

- **Art-therapy** (EXPERIMENTAL) — 16 Art-therapy sessions
- **Metacognitive therapy** (ACTIVE_COMPARATOR) — 16 Metacognitive therapy sessions

## Interventions

- **Art therapy** (BEHAVIORAL)
- **metacognitive therapy** (BEHAVIORAL)

## Primary Outcomes

- **Change in Response times between baseline and after 16 therapy sessions** _(time frame: Baseline and after 16 therapy sessions (up to 6 months))_

## Secondary Outcomes

- **Change in Clinical scales (SAPS and SANS) between baseline and after 16 therapy sessions** _(time frame: Baseline and after 16 therapy sessions (up to 6 months))_
- **Change in esthetic perception between baseline and after 16 therapy sessions** _(time frame: Baseline and after 16 therapy sessions (up to 6 months))_
- **Change in errors in visual organization tasks between baseline and after 16 therapy sessions** _(time frame: aseline and after 16 therapy sessions (up to 6 months))_

## Locations (1)

- Service de psychiatrie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.service de psychiatrie, hôpitaux universitaires de strasbourg|strasbourg||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02383095.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02383095*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*